MedTrace Logo

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

NCT06194734 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 490

Last updated 2024-03-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of KC1036 versus investigator's choice of chemotherapy in patients with advanced recurrent or metastatic esophageal squamous cell carcinoma

Conditions

Interventions

DRUG

KC1036

KC1036 60mg QD orally, before a meal, continuous administration, 21 days as a cycle

DRUG

Irinotecan

Irinotecan intravenously administered at 130-150 mg/m2 once every 2 weeks

DRUG

Docetaxel

Docetaxel intravenously administered at 60-75 mg/m2 once every 3 weeks；

DRUG

S-1

S-1 orally administered 40-60mg Bid on Day 1 to Day 14 of every 3 weeks, 21 days as a cycle

Sponsors & Collaborators

  • Beijing Konruns Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jing Huang, Ph.D · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-05
Primary Completion
2026-12-30
Completion
2027-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06194734 on ClinicalTrials.gov